Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Radiation Injuries 1Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Radiotherapy 17Specimen Handling 16Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11fludarabine 9Fluorodeoxyglucose F18 9X-Rays 8Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lisinopril × 1 year × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡